WallStreetZenWallStreetZen

NASDAQ: VYGR
Voyager Therapeutics Inc Stock

$8.51-0.29 (-3.3%)
Updated Jun 14, 2024
VYGR Price
$8.51
Fair Value Price
N/A
Market Cap
$462.89M
52 Week Low
$6.06
52 Week High
$14.07
P/E
-121.57x
P/B
1.36x
P/S
4.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$119.04M
Earnings
-$3.04M
Gross Margin
100%
Operating Margin
-11.8%
Profit Margin
-2.6%
Debt to Equity
0.38
Operating Cash Flow
$13M
Beta
1.23
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VYGR Overview

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VYGR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VYGR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VYGR is good value based on its book value relative to its share price (1.36x), compared to the US Biotechnology industry average (6.25x)
P/B vs Industry Valuation
VYGR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VYGR due diligence checks available for Premium users.

Be the first to know about important VYGR news, forecast changes, insider trades & much more!

VYGR News

Valuation

VYGR fair value

Fair Value of VYGR stock based on Discounted Cash Flow (DCF)
Price
$8.51
Fair Value
$13.17
Undervalued by
35.40%
VYGR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VYGR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-121.57x
Industry
-10.23x
Market
30.51x

VYGR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.36x
Industry
6.25x
VYGR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VYGR's financial health

Profit margin

Revenue
$19.5M
Net Income
-$11.3M
Profit Margin
-58.1%
VYGR's Earnings (EBIT) of -$14.05M... subscribe to Premium to read more.
Interest Coverage Financials
VYGR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$469.6M
Liabilities
$128.7M
Debt to equity
0.38
VYGR's short-term assets ($409.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VYGR's short-term assets ($409.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VYGR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VYGR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$58.8M
Investing
-$96.1M
Financing
$112.9M
VYGR's operating cash flow ($13.12M)... subscribe to Premium to read more.
Debt Coverage Financials

VYGR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VYGR$462.89M-3.30%-121.57x1.36x
FULC$463.04M-4.49%-4.66x2.17x
ADPT$461.26M-5.15%-2.10x1.68x
CELC$469.39M-2.02%-5.43x3.51x
VERV$455.09M-3.21%-1.89x0.78x

Voyager Therapeutics Stock FAQ

What is Voyager Therapeutics's quote symbol?

(NASDAQ: VYGR) Voyager Therapeutics trades on the NASDAQ under the ticker symbol VYGR. Voyager Therapeutics stock quotes can also be displayed as NASDAQ: VYGR.

If you're new to stock investing, here's how to buy Voyager Therapeutics stock.

What is the 52 week high and low for Voyager Therapeutics (NASDAQ: VYGR)?

(NASDAQ: VYGR) Voyager Therapeutics's 52-week high was $14.07, and its 52-week low was $6.06. It is currently -39.52% from its 52-week high and 40.43% from its 52-week low.

How much is Voyager Therapeutics stock worth today?

(NASDAQ: VYGR) Voyager Therapeutics currently has 54,393,628 outstanding shares. With Voyager Therapeutics stock trading at $8.51 per share, the total value of Voyager Therapeutics stock (market capitalization) is $462.89M.

Voyager Therapeutics stock was originally listed at a price of $17.75 in Nov 11, 2015. If you had invested in Voyager Therapeutics stock at $17.75, your return over the last 8 years would have been -52.06%, for an annualized return of -8.78% (not including any dividends or dividend reinvestments).

How much is Voyager Therapeutics's stock price per share?

(NASDAQ: VYGR) Voyager Therapeutics stock price per share is $8.51 today (as of Jun 14, 2024).

What is Voyager Therapeutics's Market Cap?

(NASDAQ: VYGR) Voyager Therapeutics's market cap is $462.89M, as of Jun 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Voyager Therapeutics's market cap is calculated by multiplying VYGR's current stock price of $8.51 by VYGR's total outstanding shares of 54,393,628.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.